Literature DB >> 23055346

Maternal serum second trimester screening for chromosomal disorders and neural tube defects in a government hospital of North India.

Gurjit Kaur1, Jyoti Srivastav, Avneet Kaur, Anju Huria, Poonam Goel, Ravinder Kaur, Sandeep Kataria, Bir Singh Chavan, Suman Kochhar, Purnima Aggarwal, Narinder Kaur, Inusha Panigrahi, Pawandeep Chawla.   

Abstract

OBJECTIVE: Down syndrome (DS) has major resource implications especially in developing countries being third most important cause of mental handicap. Maternal serum screening for chromosomal aneuploidies and neural tube defects (NTDs) is practiced worldwide in many countries and has been integrated into mainstream health care, while it is gradually gaining momentum in Asian countries.
METHODS: This prospective cohort study was carried out in pregnant women undergoing triple screening test between January 2007 and December 2010 after informed consent. Biomarkers alpha-fetoprotein, human-chorionic-gonadotropin and unconjugated-estriol were tested, and risk of pregnancy being affected with DS, Edward's syndrome or NTDs were calculated. Screen-positive patients were referred for detailed ultrasonography and confirmatory amniocentesis. Follow-up record was maintained until delivery.
RESULTS: Of 7400 pregnant women enrolled, 419(5.7%) were screen-positive, including 339 positive for DS, two for trisomy 18, and 62 for NTDs. Total eight cases of DS were eventually diagnosed in the population (prevalence of DS = 1 : 925), seven of which were detected in utero following diagnostic evaluation for positive serum screen (DR of DS screen = 87.5%). Total five cases of NTD were observed, yielding NTD prevalence of 0.67/1000.
CONCLUSIONS: Triple screening in the second trimester is reasonably effective for the detection of major chromosomal defects and NTDs, and can be implemented successfully also in India.
© 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23055346     DOI: 10.1002/pd.3984

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  7 in total

1.  DS-Connect: A Promising Tool to Improve Lives and Engage Down Syndrome Communities Worldwide.

Authors:  Emmanuel K Peprah; Melissa A Parisi; Lisa Kaeser; Sujata Bardhan; MaryLou Oster-Granite; Yvonne T Maddox
Journal:  Glob Heart       Date:  2015-08-11

Review 2.  Down Syndrome Screening in India: Are We There Yet?

Authors:  K Manikandan; Suresh Seshadri
Journal:  J Obstet Gynaecol India       Date:  2017-08-17

3.  Maternal characteristics and mid-pregnancy serum biomarkers as risk factors for subtypes of preterm birth.

Authors:  L L Jelliffe-Pawlowski; R J Baer; Y J Blumenfeld; K K Ryckman; H M O'Brodovich; J B Gould; M L Druzin; Y Y El-Sayed; D J Lyell; D K Stevenson; G M Shaw; R J Currier
Journal:  BJOG       Date:  2015-06-26       Impact factor: 6.531

4.  External Quality Assessment of Maternal Serum Levels of Alpha-Fetoprotein, Free Beta-Human Chorionic Gonadotropin, and Unconjugated Estriol in Detecting Down Syndrome and Neural Tube Defects in the Second Trimester of 87 Maternal Serum Samples, Based on 105-139 Days.

Authors:  Yiming Chen; Yijie Chen; Yezhen Shi; Wenwen Ning; Xiaoying Wang; Liyao Li; Huimin Zhang
Journal:  Med Sci Monit       Date:  2022-04-13

Review 5.  Prenatal screening for genetic disorders: Suggested guidelines for the Indian Scenario.

Authors:  Shubha R Phadke; Ratna D Puri; Prajnya Ranganath
Journal:  Indian J Med Res       Date:  2017-12       Impact factor: 2.375

6.  Estimating the burden of neural tube defects in low- and middle-income countries.

Authors:  Annie Lo; Dora Polšek; Simrita Sidhu
Journal:  J Glob Health       Date:  2014-06       Impact factor: 4.413

7.  Intellectual disability in India: Charity to right based.

Authors:  B S Chavan; Abhijit R Rozatkar
Journal:  Indian J Psychiatry       Date:  2014-04       Impact factor: 1.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.